This is a preview of subscription content, log in via an institution to check access.
Reference
Coleman CI, et al. Universal versus platelet reactivity assay- driven use of P2Y12 inhibitors in acute coronary syndrome patients. Cost-effectiveness analyses for six European perspectives. Thrombosis and Haemostasis 111: No. 1, 17 Oct 2013. Available from: URL: http://dx.doi.org/10.1160/TH13-07-0557
Rights and permissions
About this article
Cite this article
PRA-driven use of P2Y12 inhibitors the way to go in ACS. PharmacoEcon Outcomes News 690, 9 (2013). https://doi.org/10.1007/s40274-013-0836-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0836-1